Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced it will participate at the Precision Medicine World Conference (PMWC), held January 25-27, 2023, in Santa Clara, CA.
| SAN DIEGO, Jan. 25, 2023 /PRNewswire/ -- Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced it will participate at the Precision Medicine World Conference (PMWC), held January 25-27, 2023, in Santa Clara, CA.
Dr. Mathias Ehrich, Chief Medical Officer and co-founder at Juno Diagnostics, will present a company overview on Friday, January 27th, at 10:00 am PT. In addition, Todd Whitson, Executive President of Business Development and Commercial Operations, will also be attending the conference and will be available for meetings throughout the event. About Juno Diagnostics™ Juno Diagnostics™ is a category-defining health company bringing vital prenatal health information to patients by combining access, affordability, and transparency. The Company’s lead product, Juno Hazel™, is a non-invasive prenatal screening (NIPS) solution that simplifies sample collection and improves access to high-quality genetic testing results without the high cost, long lead times, and phlebotomy requirements of traditional NIPS. For more information, visit www.junodx.com and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad
SOURCE Juno Diagnostics |
View original content to download multimedia:
